PT-141 vs Viagra: they work in different places and treat different problems. Viagra (sildenafil) is a pill that boosts blood flow to the penis and is FDA-approved for erectile dysfunction (ED) in men.[2] PT-141 (bremelanotide, sold as Vyleesi) is an injection that acts on melanocortin receptors in the brain and is FDA-approved only for low sexual desire in premenopausal women.[1] No trial has compared them head to head, and PT-141 is not approved for men.
Below we compare how each works, the evidence (including PT-141’s small studies in men), timing, side effects and who might discuss which option with a clinician. For more on the peptide itself, see our PT-141 profile the sexual health peptides hub and our evidence-graded guide to the best peptides for sexual health.
At a glance
| PT-141 (Vyleesi) | Viagra (sildenafil) | Cialis (tadalafil) | |
|---|---|---|---|
| Drug class | Melanocortin receptor agonist[1] | PDE5 inhibitor[2] | PDE5 inhibitor[3] |
| Where it acts | Brain (desire and arousal pathways)[12] | Blood vessels of the penis[2] | Blood vessels of the penis[3] |
| FDA-approved for | Low sexual desire in premenopausal women (2019)[6] | Erectile dysfunction[2] | ED and enlarged prostate (BPH)[3] |
| Form | Injection under the skin[1] | Tablet[2] | Tablet[3] |
| Timing | At least 45 minutes before sex[1] | About 1 hour before (30 minutes to 4 hours)[2] | Works up to 36 hours; daily option[3] |
| Approved for men? | No[1] | Yes[2] | Yes[3] |
| Needs sexual stimulation? | Acts on desire | Yes | Yes |
How each works
Viagra, Cialis and other PDE5 inhibitors block an enzyme (PDE5) that ends an erection. With sexual stimulation, nitric oxide relaxes the blood vessels of the penis; blocking PDE5 keeps that signal going longer, so more blood flows in.[2][3] They do not create desire.
PT-141 was developed from Melanotan II, a tanning peptide, after researchers noticed it caused erections.[12] It activates melanocortin receptors in the brain, mainly MC4R, which are involved in sexual desire and arousal. The Vyleesi label notes its exact mechanism in low desire is not known.[1] Because it acts upstream of blood flow, early studies tested it in men who had not responded to Viagra.[8]
This difference matters when choosing. Erectile dysfunction is usually a problem of blood flow or nerve signals, often linked to heart disease, diabetes or medications, and PDE5 inhibitors help even when desire is normal. Low desire is a different problem, with causes that range from hormones and depression to relationship stress, and a blood-flow pill does not fix it.[4]
Evidence quality compared
PDE5 inhibitors: large, long-established trials
- Viagra was tested in 21 randomized, placebo-controlled trials in more than 3,000 men aged 19 to 87, and improved erections over placebo in all 21.[2]
- Cialis was tested in 22 trials of up to 24 weeks in more than 4,000 men.[3]
- Other options: vardenafil and avanafil are also PDE5 inhibitors, and the guideline lists further approved treatments, such as penile injections, vacuum devices and implants, for men who don’t respond.[4]
- The American Urological Association recommends PDE5 inhibitors as an option for men with ED, alongside other treatments, after shared decision-making.[4]
PT-141 in women: approved, modest effect
In two phase 3 trials of 1,267 premenopausal women, desire scores improved and distress about low desire fell more than with placebo, though the differences were modest: desire scores rose 0.30 to 0.42 points more than placebo on the trials’ scale.[5] The label says to stop treatment after 8 weeks if desire has not improved.[1]
PT-141 in men: early, small studies
| Study | Men | Result |
|---|---|---|
| Nasal PT-141, 2004 | Healthy men and men with mild to moderate ED | Doses above 7 mg produced erections vs placebo[7] |
| Injected PT-141, 2004 | Healthy men and men with an inadequate response to Viagra | Produced erections in both groups[8] |
| With sildenafil, 2005 | 19 men with ED | Low-dose nasal PT-141 plus 25 mg sildenafil beat sildenafil alone[9] |
| Viagra non-responders, 2008 | 342 men | 33.5% responded vs 8.5% on placebo; the journal later issued an expression of concern[10] |
Side effects and safety
| PT-141 (Vyleesi) | Viagra | |
|---|---|---|
| Most common | Nausea 40%, flushing 20%, injection-site reactions 13%, headache 11%[1] | Headache, flushing, indigestion, abnormal vision, nasal congestion[2] |
| Blood pressure | Short rise after each dose[1] | Can lower blood pressure, especially with alpha-blockers[2] |
| Do not combine with | Oral naltrexone (lowers its levels)[1] | Nitrates and riociguat (dangerous drop in blood pressure)[2] |
| Who should avoid | Uncontrolled high blood pressure or known heart disease[1] | Anyone using nitrates in any form[2] |
| Stopped for side effects | 18% vs 2% on placebo[1] | 2.5% vs 2.3% on placebo[2] |
| Other | Skin darkening, rare at approved dose[1] | Rare prolonged erections, sudden vision or hearing loss[2] |
Nausea with PT-141 was worst after the first dose and became much less common with later doses.[13]
Legal status and access
- Viagra and Cialis are prescription drugs approved for men with ED (and BPH for Cialis), and the AUA guideline lists them as a standard option.[2][3][4]
- Vyleesi is a prescription drug approved in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is limited to one dose in 24 hours and eight doses a month, and should be stopped after 8 weeks without improvement.[6][1]
- PT-141 for men is off-label. Any prescriber using it this way is relying on early studies, not an approval.[1]
What users report
Who each may suit: questions for your clinician
- “I have trouble getting or keeping an erection.” Ask whether a PDE5 inhibitor is suitable, and whether heart health, diabetes, hormones or medications could be involved. ED can be an early sign of heart disease.[4]
- “Viagra didn’t work for me.” Ask about dose, timing and technique first, then about other approved ED treatments the AUA guideline lists.[4]
- “My problem is desire, not erections.” For premenopausal women, Vyleesi is one approved option. For men, ask about causes such as low testosterone, depression, relationship stress or medication effects; PT-141 is not approved for them.[1][11]
- “Can I combine them?” Only with a clinician’s input; the evidence is a single 19-man study.[9]
The verdict
For erectile dysfunction, PDE5 inhibitors like Viagra and Cialis have far stronger evidence, longer safety records and approval for men. PT-141 targets desire rather than blood flow; it is approved for premenopausal women with low desire, and its benefit there is modest. In men, the idea that it might help when Viagra fails is plausible but rests on small or questioned studies. Related peptides are covered in our Melanotan II profile and our comparison of Melanotan I vs Melanotan II, two related tanning peptides (PT-141 was developed from Melanotan II).
